CuraGen Advances CR011-vcMMAE int...(ghts and uncertainties relating tocommer...),Health

Date:4/9/2008

ghts and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in CuraGen's Annual Report on Form 10-K for the year ended December 31, 2007, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, CuraGen's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward- looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Glenn Schulman, PharmD

Director of Medical Communications

gschulman@curagen.com

(888) 436-6642

CRGN-P

'/>"/>

SOURCE CuraGen Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
2. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
3. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
4. CuraGen Announces Top-Line Phase II Results on Velafermin
5. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
6. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
7. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
8. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
9. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
10. Stem Cell Breakthrough Advances Science Without Ethical Landmines, Says Cardinal
11. Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research